Clinical characteristics of patients with COVID-19 harboring detectable intracellular SARS-CoV-2 RNA in peripheral blood cells
Objectives: Although SARS-CoV-2 RNAemia has been reported to strongly impact patients with severe COVID-19, the clinical characteristics of patients with COVID-19 harboring detectable intracellular SARS-CoV-2 RNA remain unknown. Methods: We included adult patients who had developed COVID-19 between February and September 2020. Total white blood cells derived from the buffy coat of peripheral whole blood were used to detect SARS-CoV-2 RNA using the Illumina COVIDSeq test. We compared the clinical characteristics between patients with and without detected viral RNA (detected and undetected groups). Results: Among the 390 patients included, 17 harbored SARS-CoV-2 RNA in peripheral white blood cells. All 17 patients required oxygen support during the disease course and had higher intensive care unit admission (52.9% vs 28.9%, P = 0.035), mortality (17.7% vs 3.5%, P = 0.004), kidney dysfunction (severe, 23.5% vs 6.4%, P = 0.029), and corticosteroid treatment rates (76.5% vs 46.5%, P = 0.016) than those of patients in the undetected group. Conclusion: We propose that patients with circulating intracellular SARS-CoV-2 RNA in the peripheral blood exhibited the most severe disease course..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:135 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 135(2023), Seite 41-44 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hiromu Tanaka [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| doi: |
10.1016/j.ijid.2023.07.030 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ09074456X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ09074456X | ||
| 003 | DE-627 | ||
| 005 | 20240414090332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2023.07.030 |2 doi | |
| 035 | |a (DE-627)DOAJ09074456X | ||
| 035 | |a (DE-599)DOAJ219ffa2d13b84dee86d1c2564bd6ffb4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Hiromu Tanaka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical characteristics of patients with COVID-19 harboring detectable intracellular SARS-CoV-2 RNA in peripheral blood cells |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objectives: Although SARS-CoV-2 RNAemia has been reported to strongly impact patients with severe COVID-19, the clinical characteristics of patients with COVID-19 harboring detectable intracellular SARS-CoV-2 RNA remain unknown. Methods: We included adult patients who had developed COVID-19 between February and September 2020. Total white blood cells derived from the buffy coat of peripheral whole blood were used to detect SARS-CoV-2 RNA using the Illumina COVIDSeq test. We compared the clinical characteristics between patients with and without detected viral RNA (detected and undetected groups). Results: Among the 390 patients included, 17 harbored SARS-CoV-2 RNA in peripheral white blood cells. All 17 patients required oxygen support during the disease course and had higher intensive care unit admission (52.9% vs 28.9%, P = 0.035), mortality (17.7% vs 3.5%, P = 0.004), kidney dysfunction (severe, 23.5% vs 6.4%, P = 0.029), and corticosteroid treatment rates (76.5% vs 46.5%, P = 0.016) than those of patients in the undetected group. Conclusion: We propose that patients with circulating intracellular SARS-CoV-2 RNA in the peripheral blood exhibited the most severe disease course. | ||
| 650 | 4 | |a Intracellular SARS-CoV-2 RNA | |
| 650 | 4 | |a COVID-19 | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Ho Namkoong |e verfasserin |4 aut | |
| 700 | 0 | |a Shotaro Chubachi |e verfasserin |4 aut | |
| 700 | 0 | |a Shinji Irie |e verfasserin |4 aut | |
| 700 | 0 | |a Yoshifumi Uwamino |e verfasserin |4 aut | |
| 700 | 0 | |a Ho Lee |e verfasserin |4 aut | |
| 700 | 0 | |a Shuhei Azekawa |e verfasserin |4 aut | |
| 700 | 0 | |a Shiro Otake |e verfasserin |4 aut | |
| 700 | 0 | |a Kensuke Nakagawara |e verfasserin |4 aut | |
| 700 | 0 | |a Takahiro Fukushima |e verfasserin |4 aut | |
| 700 | 0 | |a Mayuko Watase |e verfasserin |4 aut | |
| 700 | 0 | |a Tatsuya Kusumoto |e verfasserin |4 aut | |
| 700 | 0 | |a Katsunori Masaki |e verfasserin |4 aut | |
| 700 | 0 | |a Hirofumi Kamata |e verfasserin |4 aut | |
| 700 | 0 | |a Makoto Ishii |e verfasserin |4 aut | |
| 700 | 0 | |a Yukinori Okada |e verfasserin |4 aut | |
| 700 | 0 | |a Tomomi Takano |e verfasserin |4 aut | |
| 700 | 0 | |a Seiya Imoto |e verfasserin |4 aut | |
| 700 | 0 | |a Ryuji Koike |e verfasserin |4 aut | |
| 700 | 0 | |a Akinori Kimura |e verfasserin |4 aut | |
| 700 | 0 | |a Satoru Miyano |e verfasserin |4 aut | |
| 700 | 0 | |a Seishi Ogawa |e verfasserin |4 aut | |
| 700 | 0 | |a Takanori Kanai |e verfasserin |4 aut | |
| 700 | 0 | |a Taka-Aki Sato |e verfasserin |4 aut | |
| 700 | 0 | |a Koichi Fukunaga |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 135(2023), Seite 41-44 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:135 |g year:2023 |g pages:41-44 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2023.07.030 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/219ffa2d13b84dee86d1c2564bd6ffb4 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S120197122300680X |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 135 |j 2023 |h 41-44 | ||